The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Prostacyclin therapies for the treatment of pulmonary arterial hypertension
Open accessAbstract
Prostacyclin and its analogues (prostanoids) are potent vasodilators and possess antithrombotic, antiproliferative and anti-inflammatory properties. Pulmonary hypertension (PH) is associated with vasoconstriction, thrombosis and proliferation, and the lack of endogenous prostacyclin may considerably contribute to this condition. This supports a strong rationale for prostanoid use as therapy for this disease. The first experiences of prostanoid therapy in PH patients were published in 1980. Epoprostenol, a synthetic analogue of prostacyclin, and the chemically stable analogues iloprost, beraprost and treprostinil were tested in randomised controlled trials. The biological actions are mainly mediated by activation of specific receptors of the target cells; however, new data suggest effects on additional intracellular pathways. In the USA and some European countries, intravenous infusion of epoprostenol and treprostinil, as well as subcutaneous infusion of treprostinil and inhalation of iloprost, have been approved for therapy of pulmonary arterial hypertension. Iloprost infusion and beraprost tablets have been approved in few other countries. Ongoing clinical studies investigate oral treprostinil, inhaled treprostinil and the combination of inhaled iloprost and sildenafil in pulmonary arterial hypertension. Combination of other targeted therapies with prostanoids appears to be effective and safe. After 25 yrs of continued knowledge, prostanoids remain a mainstay in the treatment of pulmonary arterial hypertension.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moncada, S., Gryglewski, R., Bunting, S., & Vane, J. R. (1976) · Nature · doi:10.1038/263663a0 · Cited by 3,595
Barst, R. J., Rubin, L. J., Long, W. A., McGoon, M. D., Rich, S., Badesch, D. B., Groves, B. M., Tapson, V. F., Bourge, R. C., Brundage, B. H., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602013340504 · Cited by 2,698
Kliewer, S. A., Sundseth, S. S., Jones, S. A., Brown, P. J., Wisely, G. B., Koble, C. S., Devchand, P., Wahli, W., Willson, T. M., Lenhard, J. M., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.9.4318 · Cited by 2,164
Inhaled Iloprost for Severe Pulmonary Hypertension
Olschewski, H., Simonneau, G., Galiè, N., Higenbottam, T., Naeije, R., Rubin, L. J., Nikkho, S., Speich, R., Hoeper, M. M., Behr, J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020204 · Cited by 1,783
Self-citationSIMONNEAU, G., BARST, R. J., GALIE, N., NAEIJE, R., RICH, S., BOURGE, R. C., KEOGH, A., OUDIZ, R., FROST, A., BLACKBURN, S. D., et al. (2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.165.6.2106079 · Cited by 1,441
Long-term intravenous epoprostenol infusion in primary pulmonary hypertension
Sitbon, O., Humbert, M., Nunes, H., Parent, F., Garcia, G., Hervé, P., Rainisio, M., & Simonneau, G. É. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02012-0 · Cited by 1,383
Survival in Primary Pulmonary Hypertension: The Impact of Epoprostenol Therapy
McLaughlin, V. V., Shillington, A., & Rich, S. (2002) · Circulation · doi:10.1161/01.cir.0000029100.82385.58 · Cited by 1,213
Badesch, D. B., Tapson, V. F., McGoon, M. D., Brundage, B. H., Rubin, L. J., Wigley, F. M., Rich, S., Barst, R. J., Barrett, P. S., Kral, K. M., et al. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-132-6-200003210-00002 · Cited by 1,075
Galiè, N., Torbicki, A., Barst, R. J., Dartevelle, P., Haworth, S. G., Higenbottam, T., Olschewski, H., Peacock, A. J., Pietra, G., Rubin, L. J., et al. (2004) · European Heart Journal · doi:10.1016/j.ehj.2004.09.014 · Cited by 1,053
Self-citationMedical Therapy For Pulmonary Arterial Hypertension
Badesch, D. B., Abman, S. H., Ahearn, G. S., Barst, R. J., McCrory, D. C., Simonneau, G., & McLaughlin, V. V. (2004) · Chest · doi:10.1378/chest.126.1_suppl.35s · Cited by 829
Cited by
Selexipag for the Treatment of Pulmonary Arterial Hypertension
Sitbon, O., Channick, R., Chin, K. M., Frey, A., Gaine, S., Galiè, N., Ghofrani, H.-A., Hoeper, M. M., Lang, I. M., Preiss, R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503184 · Cited by 1,060
Pulmonary hypertension in COPD
Chaouat, A., Naeije, R., & Weitzenblum, E. (2008) · European Respiratory Journal · doi:10.1183/09031936.00015608 · Cited by 625
Diagnosis, Assessment, and Treatment of Non-Pulmonary Arterial Hypertension Pulmonary Hypertension
Hoeper, M. M., Barberà, J. A., Channick, R. N., Hassoun, P. M., Lang, I. M., Manes, A., Martinez, F. J., Naeije, R., Olschewski, H., Pepke-Zaba, J., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.04.008 · Cited by 399
Self-citationNickel, N., Golpon, H., Greer, M., Knudsen, L., Olsson, K., Westerkamp, V., Welte, T., & Hoeper, M. M. (2012) · European Respiratory Journal · doi:10.1183/09031936.00092311 · Cited by 361
Hypoxic Pulmonary Vasoconstriction: Physiology and Anesthetic Implications
Lumb, A. B., & Slinger, P. (2015) · Anesthesiology · doi:10.1097/aln.0000000000000569 · Cited by 306
Metadata
- Authors
- Gomberg-Maitland, M., & Olschewski, H.
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2008-03-31
- Volume
- 31
- Issue
- 4
- Pages
- 891-901
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- OpenAlex
- W2148309043
- Cited by
- 291
- References
- 60
- FWCI
- 25.88
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prostacyclin therapies for the treatment of pulmonary arterial hypertension. https://app.cochat.ai/papers/10.1183/09031936.00097107
- The paper
- Gomberg-Maitland, M., & Olschewski, H. (2008). Prostacyclin therapies for the treatment of pulmonary arterial hypertension. European Respiratory Journal. https://doi.org/10.1183/09031936.00097107
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.